Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.

Dai C, Zhu W

Medicine1 Oct 2022Cited by 12 (Europe PMC)

PMID36316938PMCIDPMC9622638DOI10.1097/md.0000000000031334PepBankPUB-36316938

Summary

Asprosin is a newly identified adipokine with glucose-raising and appetite-enhancing effects which acts differently from the known hepatic glucose utilization pathway. This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM). This study is a non-randomized, prospective observational study. The metabolic parameters and asprosin levels were compared between 90 people with T2DM and 66 people who had normal glucose tolerance (NGT). During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks. T2DM patients were separated into a normal weight group and an overweight/obesity group to compare changes in asprosin and parameters pre- and post-treatment. The T2DM group had significantly higher fasting asprosin and 2h-postprandial asprosin levels than the NGT group (all P < .001). Fasting asprosin and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR, and negatively correlated with HDL-C in both the T2DM and NGT groups. Asprosin levels decreased after liraglutide treatment in both normal and overweight/obesity T2DM groups (all P < .001), with significantly reduced body weight and BMI in overweight/obese T2DM patients (all P < .001). Fasting and postprandial serum asprosin concentrations are higher in T2DM patients compared to normal glucose controls. Fasting and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR and negatively correlated with HDL-C in all participants. Liraglutide lowers asprosin levels in T2DM patients and can reduce weight and BMI in overweight or obese type 2 diabetics.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In normal weight adults with type 2 diabetes, serum asprosin levels decreased after liraglutide treatment.
In plain wordsIn normal weight adults with type 2 diabetes, levels of the hormone asprosin fell after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseSerum asprosin level, normal weight T2DM
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Adipokines · Metabolic and weight
Studied dose
0.6 mg/d for 2 weeks, 1.2 mg/d for 4 weeks, then 1.8 mg/d for 16 weeks · 22 weeksAs given in this study (human).
Source sentences
Summary
Asprosin levels decreased after liraglutide treatment in both normal and overweight/obesity T2DM groups
3 context sentences(design, population, supporting numbers)
Summary · context
This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM).
Summary · context
This study is a non-randomized, prospective observational study.
Summary · context
During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks.
Show in the study text Report a problemFND-3631693801
02HumanObservational studyEfficacy outcome
In overweight or obese adults with type 2 diabetes, serum asprosin levels decreased after liraglutide treatment.
In plain wordsIn overweight adults with type 2 diabetes, levels of the hormone asprosin fell after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseSerum asprosin level, overweight/obese T2DM
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Adipokines · Metabolic and weight
Studied dose
0.6 mg/d for 2 weeks, 1.2 mg/d for 4 weeks, then 1.8 mg/d for 16 weeks · 22 weeksAs given in this study (human).
Source sentences
Summary
Asprosin levels decreased after liraglutide treatment in both normal and overweight/obesity T2DM groups
3 context sentences(design, population, supporting numbers)
Summary · context
This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM).
Summary · context
This study is a non-randomized, prospective observational study.
Summary · context
During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks.
Show in the study text Report a problemFND-3631693802
03HumanObservational studyEfficacy outcome
In overweight or obese adults with type 2 diabetes, body weight was significantly reduced after liraglutide treatment.
In plain wordsIn overweight adults with type 2 diabetes, body weight fell after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight, overweight/obese T2DM
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/d for 2 weeks, 1.2 mg/d for 4 weeks, then 1.8 mg/d for 16 weeks · 22 weeksAs given in this study (human).
Source sentences
Summary
with significantly reduced body weight and BMI in overweight/obese T2DM patients (all P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM).
Summary · context
This study is a non-randomized, prospective observational study.
Summary · context
During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks.
Show in the study text Report a problemFND-3631693803
04HumanObservational studyEfficacy outcome
In overweight or obese adults with type 2 diabetes, body mass index was significantly reduced after liraglutide treatment.
In plain wordsIn overweight adults with type 2 diabetes, body mass index fell after liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody mass index, overweight/obese T2DM
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/d for 2 weeks, 1.2 mg/d for 4 weeks, then 1.8 mg/d for 16 weeks · 22 weeksAs given in this study (human).
Source sentences
Summary
with significantly reduced body weight and BMI in overweight/obese T2DM patients (all P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM).
Summary · context
This study is a non-randomized, prospective observational study.
Summary · context
During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks.
Show in the study text Report a problemFND-3631693804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.